Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $95,922.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 4,250 shares of the business’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $22.57, for a total value of $95,922.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Benjamin Hohl also recently made the following trade(s):

• On Tuesday, May 28th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $23.18, for a total value of $98,515.00.
• On Friday, May 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.50, for a total value of $22,500.00.
• On Monday, April 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $55,152.50.
• On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.72, for a total value of $346,080.00.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $21.55 on Thursday. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $26.00. The business’s 50 day moving average price is $21.93 and its two-hundred day moving average price is $17.97.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. As a group, research analysts forecast that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. AJOVista LLC acquired a new position in Enliven Therapeutics in the fourth quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Enliven Therapeutics in the 4th quarter worth $66,000. Exchange Traded Concepts LLC lifted its holdings in shares of Enliven Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after purchasing an additional 2,208 shares in the last quarter. EntryPoint Capital LLC bought a new position in shares of Enliven Therapeutics in the 1st quarter worth $167,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on the company. Robert W. Baird assumed coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 target price on the stock. Mizuho assumed coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price on the stock. Finally, Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.